GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

Testing for mismatch repair (MMR) status is crucial and should be performed in all patients with endometrial cancer (EC). Immunotherapy is approved for use, in combination with chemotherapy, in ...

As scientists question the rise in early colon cancer cases, a new study is offering some potential answers. Colored scanning electron micrograph (SEM) of a macrophage white blood cell (center ...

uterine (or endometrial), cervical, vulval and vaginal cancer. Current treatment options for ovarian cancer are limited to surgery and chemotherapy, but most patients experience recurrent ...